Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia:a single-institution experience  

作　　者：YU Wenjing 于文静(Peking Univ People′s Hosp,Peking Unive Hematol Instit,Natl Clin Res Center,Hematol Dis,Beijing Key Hematopoietic Stem Cell Transplant Lab,Beijing 100044)

机构地区：[1]Peking Univ People′s Hosp,Peking Unive Hematol Instit,Natl Clin Res Center,Hematol Dis,Beijing Key Hematopoietic Stem Cell Transplant Lab,Beijing 100044

出　　处：《China Medical Abstracts(Internal Medicine)》2022年第2期120-121,共2页中国医学文摘（内科学分册（英文版）

摘　　要：Objective To explore the safety and short-term efficacy of venetoclax combined with azacitidine (Ven+AZA) in previously untreated patients unfit for standard chemotherapy and patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) in China.Methods A retrospective study was conducted in 60 previously untreated patients unfit for standard chemotherapy and patients with R/R AML who received Ven+AZA (venetoclax, 100 mg D1, 200 mg D2, 400 mg D3-28.

关 键 词：ACUTE CHEMOTHERAPY MYELOID 

分 类 号：R733.71[医药卫生—肿瘤]